LPS-Containing analgesics and veterinary analgesics
    1.
    发明公开
    LPS-Containing analgesics and veterinary analgesics 失效
    含LPS的肠化学和兽医学

    公开(公告)号:EP0472467A3

    公开(公告)日:1993-03-17

    申请号:EP91402276.9

    申请日:1991-08-20

    IPC分类号: A61K37/20

    摘要: An analgesic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, high cholesterol level of said animal is prevented or cured; and
       a method of treating pain of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the pain of said animal.

    LPS-Containing analgesics and veterinary analgesics
    4.
    发明公开
    LPS-Containing analgesics and veterinary analgesics 失效
    LPS enthaltende Analgetika undtierärztlicheAnalgetika。

    公开(公告)号:EP0472467A2

    公开(公告)日:1992-02-26

    申请号:EP91402276.9

    申请日:1991-08-20

    IPC分类号: A61K37/20

    摘要: An analgesic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, high cholesterol level of said animal is prevented or cured; and
       a method of treating pain of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the pain of said animal.

    摘要翻译: 一种镇痛组合物,其包含有效量的至少一种LPS成员,其巨噬细胞活化ED 50为0.4-100ng / ml培养液,其鲎试验阳性LPS含量在通过测定 LPS激活体外培养的巨噬细胞的TNF产生,并绘制沿纵坐标轴的巨噬细胞活化能力(%),其中在与巨噬细胞产生的TNF的量相对应的情况下,该能力估计为0% 没有添加LPS,并且赋予巨噬细胞活化能力100%,其提供由巨噬细胞产生的TNF的最大和恒定量,并沿着横坐标绘制LPS的鲎试验阳性LPS含量以对数标度绘制, 与药学或兽医学上可接受的载体混合,使得当施用于动物时,防止所述动物的高胆固醇水平或 治愈; 以及治疗动物疼痛的方法,包括向所述动物施用一定量的上述组合物,其有效预防或治愈所述动物的绒毛。

    Cholesterol-lowering agents and veterinary cholesterol-lowering agents
    5.
    发明公开
    Cholesterol-lowering agents and veterinary cholesterol-lowering agents 失效
    Den。。。。。。。。。。。。。。。。。。。。。。。

    公开(公告)号:EP0462021A2

    公开(公告)日:1991-12-18

    申请号:EP91401622.5

    申请日:1991-06-17

    IPC分类号: A61K37/20 A61K35/78 A61K35/74

    摘要: A cholesterol-lowering composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, high cholesterol level of said animal is prevented or cured; and
       a method of treating high cholesterol level of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the high cholesterol level of said animal.

    摘要翻译: 一种胆固醇降低组合物,其包含有效量的至少一种LPS成分,其巨噬细胞活化ED 50为0.4-100ng / ml培养液,其鲎试验阳性LPS含量在通过测定能力制备的乙状曲线上观察到 的LPS以激活体外培养的巨噬细胞的TNF生产力,并绘制沿纵坐标轴的巨噬细胞活化能力(%),其中在对应于由TNFα产生的TNF的量的情况下,该能力估计为0% 没有添加LPS的巨噬细胞,100%被赋予巨噬细胞活化能力,其提供由巨噬细胞产生的TNF的最大和恒定量,并沿着横坐标绘制LPS的鲎试验阳性LPS含量为对数 与药学或兽医学上可接受的载体混合,使得当施用于动物时,所述动物的高胆固醇水平是预先 通风或治愈; 以及治疗动物的高胆固醇水平的方法,包括向所述动物施用一定量的上述有效预防或治愈所述动物的高胆固醇水平的组合物。

    LPS-containing anti-withdrawal agents
    10.
    发明公开
    LPS-containing anti-withdrawal agents 失效
    LPS enthaltenes Anti-Entzugsmittel。

    公开(公告)号:EP0533517A1

    公开(公告)日:1993-03-24

    申请号:EP92402319.5

    申请日:1992-08-20

    IPC分类号: A61K31/715 C12P19/04

    摘要: Novel antiwithdrawal agents and veterinary antiwithdrawal agents are disclosed which contain LPS representative of which having the following physical properties:
    LPS1

    Dominant molecular weight: 5,000 ± 1,000 as determined by SDS-PAGE method
    Phosphorus number: 2 ± 1 / 5,O00 (m-w.)
    Hexosamine number: 9 ± 1 / 5,000 (m.w.)
    KDO number: 2 ± 1 / 5,000 (m.w.)

    LPS2

    Dominant molecular weight: 6,500: ± 2,500 as determined by SDS-PAGE method
    Phosphorus number: 1 to 2 / 5,000 (m.w.)
    Hexosamine number: 7 ± 1 / 5,000 (m.w.)
    KDO number: 1 to 2 / 5,000 (m.w.)

    LPS3

    Dominant molecular weight: 6,500 ± 2,500 as determined by SDS-PAGE method
    Phosphorus number: 2 ± 1 / 5,000 (m.w.)
    Hexosamine number: 5 ± 1 / 5,000 (m.w.)
    KDO number: 2 ± 1 / 5,000 (m.w.)

    摘要翻译: 公开了含有代表具有以下物理性质的LPS的新型抗抽出剂和兽用抗抽穗剂:LPS1主要分子量:5,000 +/- 1,000,通过SDS-PAGE法测定磷数:2 +/- 1 / 5,000 (mw。)己糖胺数:9 +/- 1 / 5,000(mw)KDO数:2 +/- 1 / 5,000(mw)LPS2主要分子量:6,500:+/- 2,500,通过SDS-PAGE法测定磷数 :1〜2 / 5,000(mw)己糖胺数:7 +/- 1 / 5,000(mw)KDO数:1〜2 / 5,000(mw)LPS3主要分子量:6,500 +/- 2,500,通过SDS-PAGE法测定 磷数:2 +/- 1 / 5,000(mw)己糖胺数:5 +/- 1 / 5,000(mw)KDO数:2 +/- 1 / 5,000(mw)e